Literature DB >> 8564223

Relaxin-induced increased coronary flow through stimulation of nitric oxide production.

T Bani-Sacchi1, M Bigazzi, D Bani, P F Mannaioni, E Masini.   

Abstract

1. Relaxin (RLX) is a multifunctional hormone which, besides its role in pregnancy and parturition, has also been shown to influence the cardiovascular system. In this study, we investigated the effect of RLX on coronary flow of rat and guinea-pig hearts, isolated and perfused in a Langendorff apparatus. RLX was either added to the perfusion fluid at a concentration of 5 x 10(-9) M for a 20-min perfusion, or given as a bolus into the aortic cannula at concentrations of 10(-9) M, 5 x 10(-8) M dissolved in 1 ml of perfusion fluid. 2. RLX, given either for a 20-min perfusion or as a bolus in the aortic cannula to guinea-pig and rat isolated hearts, increased the coronary flow and the amount of nitrite, a stable end-product of nitric oxide (NO) metabolism, that appeared in the perfusates in a concentration-dependent fashion. 3. The increase in coronary flow and in nitrite in the perfusates induced by RLX was significantly reduced by pretreatment with the nitric oxide synthase (NOS) inhibitor, NG-monomethyl-L-arginine (L-NMMA, 10(-4) M). 4. The effects of RLX on coronary flow and nitrite amounts in the perfusates were compared with those induced by the endothelium-dependent vasodilator agent, acetylcholine (ACh, 10(-8)-10(-7) M), and by the endothelium-independent vasodilator agent, sodium nitroprusside (SNP, 10(-7)-10(-6) M). The results obtained show that RLX is more effective than ACh and SNP in increasing coronary flow. 5 The results of this study show that RLX increases coronary flow through stimulation of NO production; hence this hormone should be regarded as a novel agent capable of improving myocardial perfusion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564223      PMCID: PMC1908915          DOI: 10.1111/j.1476-5381.1995.tb16377.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Short-term desensitization of the histamine H1 receptor in human HeLa cells: involvement of protein kinase C dependent and independent pathways.

Authors:  M J Smit; S M Bloemers; R Leurs; L G Tertoolen; A Bast; S W de Laat; H Timmerman
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

2.  Purification and characterization of porcine relaxin.

Authors:  C D Sherwood; E M O'Byrne
Journal:  Arch Biochem Biophys       Date:  1974-01       Impact factor: 4.013

3.  Effect of coronary perfusion rate on the hydrolysis of exogenous and endogenous acetylcholine in the isolated heart.

Authors:  H A Dieterich; K Löffelholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-01       Impact factor: 3.000

Review 4.  Endogenous myocardial protective (antiarrhythmic) substances.

Authors:  J Parratt
Journal:  Cardiovasc Res       Date:  1993-05       Impact factor: 10.787

Review 5.  Relaxin as a new hormone.

Authors:  G D Bryant-Greenwood
Journal:  Endocr Rev       Date:  1982       Impact factor: 19.871

6.  Morphological changes induced in mouse mammary gland by porcine and human relaxin.

Authors:  G Bani; M Bigazzi
Journal:  Acta Anat (Basel)       Date:  1984

7.  Expression of relaxin mRNA and relaxin receptors in postnatal and adult rat brains and hearts. Localization and developmental patterns.

Authors:  P L Osheroff; W H Ho
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

8.  Relaxin increases rat heart rate by a direct action on the cardiac atrium.

Authors:  D G Ward; G R Thomas; M J Cronin
Journal:  Biochem Biophys Res Commun       Date:  1992-07-31       Impact factor: 3.575

9.  Radioimmunoassay of relaxin throughout pregnancy and during parturition in the rat.

Authors:  O D Sherwood; V E Crnekovic; W L Gordon; J E Rutherford
Journal:  Endocrinology       Date:  1980-09       Impact factor: 4.736

10.  Effects of relaxin on mast cells. In vitro and in vivo studies in rats and guinea pigs.

Authors:  E Masini; D Bani; M Bigazzi; P F Mannaioni; T Bani-Sacchi
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more
  37 in total

1.  Relaxin is a potent renal vasodilator in conscious rats.

Authors:  L A Danielson; O D Sherwood; K P Conrad
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

2.  Relaxin is essential for renal vasodilation during pregnancy in conscious rats.

Authors:  J Novak; L A Danielson; L J Kerchner; O D Sherwood; R J Ramirez; P A Moalli; K P Conrad
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.

Authors:  E Masini; G Zagli; J F Ndisang; M Solazzo; P F Mannaioni; D Bani
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 4.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 5.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

6.  Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart.

Authors:  D Bani; E Masini; M G Bello; M Bigazzi; T B Sacchi
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 7.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

8.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

Review 9.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

10.  Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.